Is saliva serology useful for the diagnosis of *Helicobacter pylori*?

J M L Christie, C A M McNulty, N A Shepherd, R M Valori

Abstract

Background—The Cortecs Diagnostics Helisal Assay test is a quantitative immunoassay for salivary IgG antibodies against *Helicobacter pylori*. Saliva can be obtained simply with the kit in the general practitioners surgery.

Aims—To compare the new saliva serological test for *H pylori* with 'gold standard' evidence of *H pylori* infection (antral biopsy specimens for histology, culture, and urease test) and a new serum serological test.

Patients—Eighty six unselected dyspeptic patients undergoing endoscopy.

Methods—Each patient provided saliva and serum before endoscopy for *H pylori* serology, which was compared against 'gold standard' evidence of infection.

Results—Thirty two patients were *H pylori* positive by the 'gold standard' tests. At a cut off value of 0.15 EU/ml the saliva test had a sensitivity of 88% and a specificity of 71%, with a negative predictive value of 90%. If patients who were taking omeprazole or had recent antibiotics are excluded, the sensitivity is unchanged but the specificity increases to 79%. The serum test had a similar sensitivity of 85% but better specificity of 78%.

Conclusion—Serum testing remains the best serological test for *H pylori* in the hospital setting. Saliva testing may have a role in epidemiological studies and in screening dyspeptic patients in general practice, especially in children in whom venesection is more difficult.

(Gut 1996; 39: 27-30)

Keywords: *Helicobacter pylori*, serology, saliva.

Since *Helicobacter pylori* was first isolated from human gastric biopsy material in 1982,¹ the gold standard diagnostic test has remained histological analysis and culture of antral biopsy specimens.² These techniques are invasive and may take 24-72 hours, and therefore there is a need for a good serological test that would avoid the need for endoscopy. The systemic hormonal antibody response to *H pylori* is well documented and correlates well with infection.³⁻⁵ Enzyme linked immunosorbent assay (ELISA) has been used widely in epidemiological studies and more recently for monitoring the longterm outcome of *H pylori* therapeutic regimens.⁶ Sobala's proposal to perform *H pylori* serology on all patients under 45 years referred for endoscopy reduced workload by 30%.⁷ Workload could be reduced

further by raising the cut off to 55 years without reducing the detection of malignant disease.⁸ Dyspeptic patients who purchase over the counter H₂ antagonists may benefit from *H pylori* eradication rather than repeat self treatment with cimetidine. A simple serological test to assess their *H pylori* status would therefore be very useful to general practitioners.

We evaluated a new saliva test for the diagnosis of *H pylori*, comparing this with gold standard evidence of *H pylori* and also with a serum serological test. The Cortecs Diagnostics Helisal Assay is a quantitative immunoassay for the measurement of salivary IgG antibodies against *H pylori*. Saliva collection has the advantage of being a non-invasive simple test that can be easily performed in the general practice setting; collection is easy for patients and health care personnel and greatly reduces the risk of bloodborne infections.

Methods

Eighty six unselected patients undergoing endoscopy at Gloucestershire Royal Hospital for investigation of dyspepsia took part. Blood and saliva were taken prior to endoscopy. At endoscopy, three antral biopsy specimens were taken for urease test, culture, and histology.⁹ If any one of these 'gold standard' tests were positive, the patients were deemed *H pylori* positive. The predictive value of the saliva test was compared with these gold standard tests, as well as a serum serological test.

The saliva was collected using an Omni-Sal collection device; this resembles an absorbent lollipop. The device is placed in the mouth for approximately 2-5 minutes. When enough saliva has been produced, the tip of the device turns from white to blue. The device is then placed into a separator tube containing buffer, and can be stored at room temperature for up to one month. All sera were stored in aliquots at -20°C until assayed.

Plastic microwells coated with antigens extracted from *H pylori* were incubated with control/standard solutions and the samples of human saliva for 30 minutes. Salivary (IgG) antibodies to *H pylori* present in the samples become bound to antigen on the microwells. The microwells are then washed five times with working wash solution using a manual or automated plate washer (333-500 µl/well) to remove unbound material. A second incubation then takes place with biotinylated antibody to human IgG for 30 minutes. The wells are then washed as before, and a third incubation for 15 minutes with streptavidin labelled (HRP) enzyme conjugate is performed. Excess enzyme conjugate is again removed by washing

Gloucester
Gastroenterology
Group,
Gloucestershire Royal
Hospital, Gloucester
J M L Christie
C A M McNulty
N A Shepherd
R M Valori

Correspondence to:
Dr J Christie, c/o Dr
Chapman's secretary, John
Radcliffe Hospital, Oxford
OX3 9DU.

Accepted for publication
30 January 1996

Figure 1: Salivary ELISA values in patients with or without gold standard evidence of *H. pylori*.

and a substrate solution containing tetramethylbenzidine (TMB) and hydrogen peroxide is added to the wells and incubated for 15 minutes. In the presence of HRP enzyme, TMB gives a blue colour that turns yellow and intensifies on addition of stop solution. The intensity of the colour is proportional to the amount of salivary *H. pylori* (IgG) antibody in the sample. The absorbance value of each assay well is measured in a plate reader (A 450 nm).

A standard curve can be provided using the high standard solution which contains 4.0 ELISA units/ml (EU) of anti-*H. pylori* activity, and sequentially diluting it with diluent solution to produce a standard curve at suggested concentrates of 4.0, 2.0, 1.0, 0.5, 0.25 ELISA units. A quantitative assay can then be performed by plotting mean absorbance values against ELISA unit values of the standard curve.

Results

Thirty two of 86 patients endoscoped were *H. pylori* positive by either urease test, culture

or histology. In the *H. pylori* positive group, there were four patients with duodenal ulceration and one case of gastric ulceration. There was one case of superficial duodenal ulceration and no cases of gastric ulceration in the *H. pylori* negative group.

In the group of 86 patients, not all gave both blood and saliva and therefore, in the analysis there is a small discrepancy in the total number of salivary tests compared with serum tests.

The mean (SD) salivary IgG titre for *H. pylori* positive and negative patients was 1.16 (1.46) and 0.171 (0.251) respectively. These results are significantly different with p value of less than 0.005. The mean (SD) serum IgG titre for *H. pylori* positive and negative patients was 5.02 (4.03) and 0.68 (0.92) respectively, which is also significantly different ($p > 0.005$). Figure 1 shows the EU values for the saliva samples. The Table shows the sensitivity and specificity of the salivary IgG assay with alternative cut off values for the test (0.15 and 0.30 EU/ml) along with the results of the serum test. Figure 2 shows the changes in sensitivity and specificity for different cut off values of the ELISA salivary test. The optimal cut off point of 0.15 EU/ml gave a sensitivity of 88% and a specificity of 71%, with a negative predictive value of 90%. The sensitivity and specificity for the serum test was 85% and 78% at 1.0 EU/ml cut off (the manufacturer's recommended cut off), with a positive predictive value of 68% and a negative predictive value of 91%.

On review of the histology, five of 15 false positive saliva tests had histology suggestive of either present or past *H. pylori* infection (chronic active gastritis, lymphoid aggregation, and intestinal metaplasia), although *H. pylori* infection was not seen. Including these patients as *H. pylori* positive gives the saliva test a sensitivity of 89% and specificity of 79%.

The study was conducted by assessing consecutive patients attending the endoscopy department without any exclusion criteria. However if patients who were taking omeprazole or who had taken recent antibiotics are excluded from the analysis the saliva test has an improved sensitivity of 88% and specificity of 79% at the 0.15 EU cut off.

The overall prevalence of *H. pylori* in all ages was 40% in our study. The changes in positive predictive value and negative predictive value for the salivary ELISA test can be calculated for different prevalences of *H. pylori* and is shown in Figure 3. The test performs best at a prevalence of around 55%.

Discussion

In this study we compared salivary and serum *H. pylori* IgG ELISA with histological and culture evidence of *H. pylori* colonisation of the antral mucosa. For the saliva test, a cut off value of 0.15 EU/ml gave the best results with a sensitivity of 88%, although the specificity was poor at 71%. At this cut off the test only failed to detect four *H. pylori* positive patients, which were also missed by the serum test. There were a large number of false positive

Performance characteristics of saliva and serum antibody ELISA test

		Gold standard		Sensitivity	Specificity	PPV	NPV
		+ve	-ve				
Saliva test	0.15 EU/ml	+ve	28	15	88	71	65
	Cut off	-ve	4	37			
	0.3 EU/ml	+ve	22	5	69	90	81
	Cut off	-ve	10	47			
	Serum test	+ve	23	11	85	78	68
		-ve	4	40			91

PPV=positive predictive value, NPV=negative predictive value.

Figure 2: Changes in sensitivity and specificity with different cut off values for the *H pylori* saliva serology test.

results. This high false positive rate is the main disadvantage of the test and there are a number of possible explanations for this. Firstly, the biopsy specimens may have failed to detect *H pylori* because of patchy infection. In our study three antral biopsy specimens were taken; one for the urease test, one for histology, and one for culture. If two biopsies for each of these tests had been performed, as well two biopsies from the body of the stomach, there may have been a higher pick up of *H pylori* by the 'gold standard' tests, thus reducing the high false positive rate of the saliva test.

Secondly, in five of these patients the histology was suggestive of *H pylori* infection, in that chronic active gastritis with lymphocytic infiltration was seen, although *H pylori* organisms were not identified. In three of these patients intestinal metaplasia was present, which is known to be associated with reduced levels of *H pylori*. The 'gold standard' tests may again be failing to detect *H pylori*. Indeed if these patients were *H pylori* positive, the saliva test would have an improved sensitivity of 89% and specificity of 79%.

Thirdly, patients who have had eradication therapy for *H pylori* (and this may even have

been inadvertent) may remain antibody positive but be biopsy negative for *H pylori* for at least six months after treatment.¹⁰ Reviewing the hospital notes, five of the patients with false positive results had documented antimicrobials active against *H pylori* prior to endoscopy. Fourthly, three of the patients with false positive results were receiving longterm omeprazole treatment, which can suppress the levels of *H pylori* and make detection more difficult. Our study was designed to assess the use of the saliva test in a district general endoscopy service and there were no exclusion criteria for patients. However inclusion of patients who have received recent antibiotics or are taking omeprazole in a validation study would tend to bias against the test. Fifthly, periodontal disease where capillary permeability is increased or gum bleeding can lead to high titres of salivary IgG and thus to false high readings for IgG to *H pylori*.¹¹

Although the specificity of the saliva test improves at the 0.3 EU/ml cut off value, the sensitivity of the test at this value of 69% renders the test inadequate for practical purposes. At the 0.15 EU/ml cut off value, the negative predictive value of 90% does give the saliva test a useful place for screening in general practice. A negative saliva test would indicate lack of *H pylori* colonisation, making peptic ulcer disease unlikely in the young dyspeptic patient and reducing the need for endoscopy.⁷ Indeed the saliva test detected all cases of duodenal ulceration in our study.

Our serum results compare similarly with other commercial tests for *H pylori* IgG antibody detection.¹² The sensitivity of the saliva test (0.15 EU/ml) and serum test is similar. The sensitivity of the test may be improved by modification of the antigen. Generally the use of single purified antigens such as urease or the 120 KDa surface protein are very specific but have lower sensitivity. This is because the antibody response to any single antigen is variable from patient to patient. Indeed a small number of patients will never produce a circulating antibody response to *H pylori*. The better specificity of the serum test makes it the superior test and therefore the gold standard serological test in the hospital setting. In many ways this is to be expected as the concentration of immunoglobulins in saliva is much lower than in serum.¹³ Further development of the salivary assay, which takes into account the relative proportion of *H pylori* specific IgG to total IgG could improve the performance of the test especially helping to distinguish false high results because of periodontal disease.¹⁴ More sensitive assays for viral antibodies in saliva have been performed using IgG capture radioimmunoassays (GACRIA), which have been shown to be superior to enzyme linked immunosorbent assays in the detection of salivary IgG to hepatitis A and B, HIV, and rubella virus.¹⁵ Modification to the test reported here has now been incorporated into the tests to improve its efficiency, using the cut off of 0.15 EU/ml.

Saliva has the advantage of being easier to collect and store, lending itself to widespread

Figure 3: Projected changes in the predictive values of the saliva test with different prevalences of *H pylori*.

use in the community and in epidemiological studies. It would be useful for studies in children where screening with serum would be more difficult. Unlike serum, which needs to be separated within a few hours from blood cells, saliva samples could be collected and posted and batched for up to a month before testing.

The sensitivity of this saliva test is the same as that recently described by Patel.¹⁶ However, the prevalence of *H pylori* in their study was 50%, near to the optimum for both tests. Our study was undertaken in an endoscopy population in which the prevalence of *H pylori* was 40%. As the prevalence of *H pylori* would be expected to be lower in general practice than an endoscopy population the negative predictive value of the test in this setting should be higher making it a valuable screening test in this setting – but the positive predictive value would be much lower (Fig 3). Although our test detected all patients with peptic ulceration we would still suggest that not only the test be modified to improve its specificity but that further work is done to evaluate its predictive value in general practice to determine the role of such a test in patient management and screening.

We thank the endoscopy and public health laboratory staff for the extra work involved in collecting and processing specimens. This study was sponsored by Cortecs, UK.

- 1 Warren J, Marshall B. Unidentified curved bacillus on gastric epithelium in chronic active gastritis. *Lancet* 1983; i: 1273–5.

- 2 Barthel JS, Everett ED. Diagnosis of *Campylobacter pylori* infections: the 'gold standard' and the alternatives. *Rev Infect Dis* 1990; 12: S107–14.
- 3 Perez-Perez GI, Dworkin BM, Chodes JE, Blaser MJ. *Campylobacter pylori* antibodies in humans. *Ann Intern Med* 1988; 109: 11–7.
- 4 Wyatt JL, Rathbone BJ. The role of serology in the diagnosis of *Campylobacter pylori* infection. *Scand J Gastroenterol* 1989; 24: S27–34.
- 5 Goodwin CS, Blincow E, Peterson G, Sanderson C, Cheng W, Marshall B, *et al.* Enzyme-linked immunosorbent assay for *Campylobacter pyloridis*: correlation with the presence of *C pyloridis* in the gastric mucosa. *J Infect Dis* 1987; 155: 488–94.
- 6 Veenendaal RA, Pena AS, Meijer JL, Endtz H Ph, van der Est MMC, van Duin W *et al.* Longterm serological surveillance after treatment of *Helicobacter pylori* infection. *Gut* 1991; 32: 1291–4.
- 7 Sobala GM, Crabtree JE, Pentith JA, Rathbone BJ, Shallcross TM, Wyatt JL, *et al.* Screening dyspepsia by serology to *Helicobacter pylori*. *Lancet* 1991; 338: 94–6.
- 8 Christie J, Codling B, Valori R. Gastric cancer below the age of 55 is rare and is not worth screening for. *Gut* 1994; 35 (suppl 2): S24.
- 9 McNulty CAM, Dent JC, Uff JS, Gear MWL, Wilkinson SP. Detection of *Campylobacter pylori* by the biopsy urease test: an assessment of 1445 patients. *Gut* 1989; 30: 1058–62.
- 10 Glupczynski Y, Burette A, Goossens H, DePrez C, Butzler JP. Effect of antimicrobial therapy on the specific serological response to *Helicobacter pylori* infection. *Eur J Clin Microbiol Infect Dis* 1992; 7: 583–8.
- 11 Perry KR, Parry JV, Mortimer PP, Peters TJ. The influence dental status on the detection of IgG class antiviral antibodies in human saliva. *Arch Oral Biol* 1991; 36: 221–6.
- 12 Jensen AKV, Andersen LP, Wachmann CH. Evaluation of eight commercial kits for *Helicobacter pylori* IgG antibody detection. *APMIS* 1993; 101: 795–801.
- 13 Shillitoe EJ, Lehner T. Immunoglobulins and complement in crevicular fluid, serum and saliva in man. *Arch Oral Biol* 1972; 17: 241–7.
- 14 Parry JV, Perry KR, Mortimer PP. Sensitive assays for viral antibodies in saliva: an alternative to tests on serum. *Lancet* 1987; ii: 72–5.
- 15 Perry KJ, Brown DWG, Parry JV, Panday S, Pipkin C, Richards A. Detection of measles, mumps and rubella antibodies in saliva using antibody capture radioimmunoassay. *J Med Virol* 1993; 40: 235–40.
- 16 Patel P, Mendall MA, Khulusi S, Molineaux N, Levy J, Maxwell JD, *et al.* Salivary antibodies to *Helicobacter pylori*: screening dyspeptic patients before endoscopy. *Lancet* 1994; 344: 511–5.